Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

Avalo Therapeutics (AVTX) R&D In Process (2018 - 2024)

Avalo Therapeutics (AVTX) has disclosed R&D In Process for 2 consecutive years, with $103000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, R&D In Process changed N/A year-over-year to $103000.0, compared with a TTM value of $103000.0 through Mar 2025, down 99.63%, and an annual FY2024 reading of $27.6 million, changed N/A over the prior year.
  • R&D In Process was $103000.0 for Q2 2024 at Avalo Therapeutics, down from $27.5 million in the prior quarter.
  • Across five years, R&D In Process topped out at $27.5 million in Q1 2024 and bottomed at $103000.0 in Q2 2024.